The latest, highly contagious subvariants are driving infections, but new vaccines may help stem the tide of another wave — ...

Novavax, Inc. (Nasdaq: NVAX), a global company advancing protein-based vaccines with its Matrix-M™ adjuvant, today announced ...

The Food and Drug Administration (FDA) granted emergency use authorization for an updated version of the Novavax COVID-19 ...

The newly approved vaccine targets multiple circulating variants, promising enhanced protection and availability across ...

Reuters.com is your online source for the latest news stories and current events, ensuring our readers up to date with any ...

Friday, the FDA granted Emergency Use Authorization to Novavax Inc.’s (NASDAQ:NVAX) COVID-19 Vaccine, Adjuvanted (2024-2025 ...

Unlike Pfizer/BioNTech and Moderna, Novavax does not use mRNA technology for its COVID-19 vaccine, instead opting for a ...

The protein-based shot represents a non-mRNA option for the 2024-2025 season, and follows the agency's recent approvals and ...

The US regulatory agency has also approved updated versions of Moderna and Pfizer / BioNTech’s Covid-19 vaccines in the past ...

Novavax currently carries a Zacks Rank #3 (Hold). You can see the complete list of today’s Zacks #1 Rank (Strong Buy) stocks here. Each was handpicked by a Zacks expert as the #1 favorite stock to ...

The U.S. Food and Drug Administration on Friday granted emergency use authorization for an updated version of Novavax's COVID ...

The Food and Drug Administration (FDA) has authorized the emergency use of the Novavax COVID-19 Vaccine, Adjuvanted.